The main triggers act to boost acetylcholine levels in the brain. These include Galantamine, GPC, and nicotine. A second class of triggers acts to boost norepineprhine in the brain. This would be Yohimbine. The triggers only work if taken under the right set of circumstances. The supporting supplements either suppress REM sleep prior to an attempt (5-htp and/or melatonin) or boost dopamine levels (Mucuna Pruriens).
Specifically Mr. LaBerge’s patent covered AChE inhibitors. These substances, of which Galantamine is one, prevent the break down of acetylcholine.
Here is some useful information contained in the patent:
and I quote:
"A method of enhancing lucid dreaming comprising administration to individuals the Acetylcholine Esterase inhibitor class of drugs. Use of therapeutic agents recently developed for Alzheimer"s Disease such as Donepizil (Aricept.RTM.), Rivastigmin (Exelon.RTM.), Galantamine (Reminyl.RTM., Nivalin.RTM.), and Huperzine results in minimal side-effects (e.g., insomnia and gastrointestinal symptoms) while significantly enhancing dreaming cognitive clarity, lucidity, self-reflection, recall, control, bizarreness, and visual vividness."
[0012] This invention relates to the field of Lucid Dreaming and the enhancement of dream recall and dream lucidity through memory enhancing drugs, including the class of substances that comprise Acetylcholine Esterase inhibitors (AChEls). Lucid dreaming involves dreaming while knowing that you are dreaming. AChE inhibitors (AchEl's) inhibit the normal metabolic inactivation of Acetylcholine (ACh) by inhibiting the enzyme, Acetylcholine Esterase (AChE), leading to accumulation of Ach. AchEl's are most commonly used to enhance memory, particularly in patients suffering from Alzheimer's disease. Ach is also well known to be important in REM and thus is suggested herein to enhance dreaming and lucidity. "
end quote.
The following is a summary of an experiment using Donepizil. Donepizil is also an AChE inhibitor but it available only by prescription.
and I quote:
"[0013] While investigating the efficacy of donepizil (Aricept.RTM.) as a means to enhance lucid dreaming and cognitive clarity during REM sleep in normal subjects, the following experiment was performed with the following results: A randomized, double blind, placebo-controlled crossover trial was performed with ten normal volunteers self-selected for high dream recall and interest in lucid dreaming (7 male, 3 female, age 22-55). Subjects collected dream content and other self-report measures on three nights, separated by a washout period of at least one week. At bedtime, they took capsules containing 0 (placebo), 5, or 10 mg of donepizil, with counter-balanced order of the three dosages. After each spontaneous awakening during the three nights, Ss evaluated dream content on a range of measures including bizarreness, complexity, and intensity, affect, cognitive clarity, lucidity, and control. They also estimated sleep quality, insomnia, and degree of any adverse effects.
[0014] RESULTS: Nine of the 10 Ss (90%) reported one or more lucid dreams on the experimental nights, with only one S reporting a lucid dream on a placebo night. Cognitive clarity, lucidity, recall, control, bizarreness, and visual vividness were all significantly elevated with donepizil compared to placebo. The effects were generally dose-related with 10 mg donepizil producing significantly higher levels of these variables than the 5 mg dose, which in turn produced significant elevations compared to placebo. Odds of lucid dreaming for the three conditions increased from 0.031 for placebo, to 0.429 for 5 mg donepizil, and 0.754 for 10 mg donepizil. "
end quote"
Happy dreaming.
Thomas
|
|
Bookmarks